MDX 220
Alternative Names: HCC49XH22Latest Information Update: 27 Apr 2005
Price :
$50 *
At a glance
- Originator National Cancer Institute (USA)
- Developer IDM S.A.; National Cancer Institute (USA)
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Glycoprotein inhibitors; IgG receptor antagonists; Neoplasm antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Apr 2005 Discontinued - Phase-II for Cancer in USA (unspecified route)
- 07 Apr 2003 No development reported - Phase-II for Cancer in USA (unspecified route)
- 18 Feb 2000 IDM will acquire worldwide rights to MDX 220 as part of an expanded oncology agreement with Medarex